FR2469177A1 - Composition derivee d'acide aromatique, d'acide aromatique phenol et d'acide-alcool aliphatique ayant des proprietes antitumorales et preparation pharmaceutique la contenant - Google Patents
Composition derivee d'acide aromatique, d'acide aromatique phenol et d'acide-alcool aliphatique ayant des proprietes antitumorales et preparation pharmaceutique la contenant Download PDFInfo
- Publication number
- FR2469177A1 FR2469177A1 FR7920541A FR7920541A FR2469177A1 FR 2469177 A1 FR2469177 A1 FR 2469177A1 FR 7920541 A FR7920541 A FR 7920541A FR 7920541 A FR7920541 A FR 7920541A FR 2469177 A1 FR2469177 A1 FR 2469177A1
- Authority
- FR
- France
- Prior art keywords
- acid
- composition according
- composition
- metal
- initial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 15
- 239000002184 metal Substances 0.000 title claims abstract description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 229910052712 strontium Inorganic materials 0.000 title claims abstract description 6
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 125000001931 aliphatic group Chemical group 0.000 title claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 title abstract description 11
- 201000004624 Dermatitis Diseases 0.000 title abstract description 3
- 201000004681 Psoriasis Diseases 0.000 title abstract description 3
- 208000010668 atopic eczema Diseases 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 239000000470 constituent Substances 0.000 claims abstract description 16
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 150000007942 carboxylates Chemical class 0.000 claims abstract description 8
- 238000011065 in-situ storage Methods 0.000 claims abstract description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 229940074391 gallic acid Drugs 0.000 claims abstract description 5
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 4
- 238000002083 X-ray spectrum Methods 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229940031826 phenolate Drugs 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 238000004817 gas chromatography Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000004707 phenolate Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 16
- 238000001959 radiotherapy Methods 0.000 abstract description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000005711 Benzoic acid Substances 0.000 abstract description 3
- 235000010233 benzoic acid Nutrition 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 208000008771 Lymphadenopathy Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009200 cobalt therapy Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000018555 lymphatic system disease Diseases 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 208000001126 Keratosis Diseases 0.000 description 3
- 230000002927 anti-mitotic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 239000003080 antimitotic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 241001289435 Astragalus brachycalyx Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000173347 Tonsilla Species 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003065 pyriform sinus Anatomy 0.000 description 1
- 208000006934 radiodermatitis Diseases 0.000 description 1
- 230000005810 radionecrosis Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910000018 strontium carbonate Inorganic materials 0.000 description 1
- 150000003438 strontium compounds Chemical class 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- CCUZKVDGQHXAFK-UHFFFAOYSA-L strontium;2-hydroxypropanoate Chemical compound [Sr+2].CC(O)C([O-])=O.CC(O)C([O-])=O CCUZKVDGQHXAFK-UHFFFAOYSA-L 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7920541A FR2469177A1 (fr) | 1979-08-10 | 1979-08-10 | Composition derivee d'acide aromatique, d'acide aromatique phenol et d'acide-alcool aliphatique ayant des proprietes antitumorales et preparation pharmaceutique la contenant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7920541A FR2469177A1 (fr) | 1979-08-10 | 1979-08-10 | Composition derivee d'acide aromatique, d'acide aromatique phenol et d'acide-alcool aliphatique ayant des proprietes antitumorales et preparation pharmaceutique la contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2469177A1 true FR2469177A1 (fr) | 1981-05-22 |
| FR2469177B1 FR2469177B1 (enExample) | 1981-12-18 |
Family
ID=9228800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7920541A Granted FR2469177A1 (fr) | 1979-08-10 | 1979-08-10 | Composition derivee d'acide aromatique, d'acide aromatique phenol et d'acide-alcool aliphatique ayant des proprietes antitumorales et preparation pharmaceutique la contenant |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2469177A1 (enExample) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2128325A1 (en) * | 1971-03-01 | 1972-10-20 | Comar Michel | Anticancer agents - contg acetylene-dicarboxylic acid and/or mellitic acid or their derivs |
-
1979
- 1979-08-10 FR FR7920541A patent/FR2469177A1/fr active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2128325A1 (en) * | 1971-03-01 | 1972-10-20 | Comar Michel | Anticancer agents - contg acetylene-dicarboxylic acid and/or mellitic acid or their derivs |
Non-Patent Citations (1)
| Title |
|---|
| EXBK/61 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2469177B1 (enExample) | 1981-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niles et al. | Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth | |
| EP2441454B1 (en) | The use of isothiocyanate compounds in treating prostatitis | |
| Dam et al. | Intramuscular administration of phenytoin | |
| JP2017101070A (ja) | Ｆｒａｘｉｎｕｓ ｅｘｃｅｌｓｉｏｒ種子の抽出物とその治療適用 | |
| Zhang et al. | Exploring the immunometabolic potential of Danggui Buxue Decoction for the treatment of IBD-related colorectal cancer | |
| JP2013071909A (ja) | 脳内過酸化脂質蓄積抑制剤 | |
| WO2003072120A1 (en) | The use of the total coumarins of cnidium monnieri in preparation of the medicament for treating psoriasis | |
| Xie et al. | Long-term treatment with L-isoleucine or L-leucine in AIN-93G diet has promoting effects on rat bladder carcinogenesis | |
| JP7031867B2 (ja) | トリテルペノイドを含む組成物 | |
| FR2469177A1 (fr) | Composition derivee d'acide aromatique, d'acide aromatique phenol et d'acide-alcool aliphatique ayant des proprietes antitumorales et preparation pharmaceutique la contenant | |
| CN109731019B (zh) | 一种具有化疗增效作用的组合物，包括组成、制备及应用 | |
| CN114949105B (zh) | 一种用于防治因放化疗导致口腔黏膜炎的药物牙膏 | |
| FR2987264A1 (fr) | Methodes et compositions pour le traitement des metastases cancereuses | |
| US20040101584A1 (en) | Control of cancer with annonaceous extracts | |
| US11554132B2 (en) | Compositions comprising resveratrolosides and curcumins | |
| CN113694109A (zh) | 一种复方黄柏药物制剂、制备方法及应用 | |
| JPH04211013A (ja) | スティグマスタ−４−エン−３−オンを含む薬剤およびその用途 | |
| TWI815349B (zh) | 山竹果殼萃取物用於製備促進糖尿病傷口癒合的藥物的用途 | |
| FR2710266A1 (fr) | Nouvelles compositions en cosmétologie et dermatologie proposées dans le traitement des verrues. | |
| CN115364097B (zh) | 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用 | |
| CN112022865B (zh) | 白头翁皂苷b4在制备治疗糖尿病皮肤溃疡的药物中的用途 | |
| US4727087A (en) | Pharmaceutical composition and method of treatment | |
| Rosa et al. | Short-chain fatty acids regulate tight junction proteins of small intestinal organoids through hdac and stat3 | |
| Kirschner et al. | Compartmental tracer enrichment data analysis to measure intestinal short-chain fatty acid (scfa) production in health and disease | |
| WO2004006937A2 (fr) | Compositions pharmaceutiques a base d'inhibiteurs de la 5-alpha-reductase et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |